Filing Flows

Filing Flows › Companies › Lemaitre Vascular › Cash flow

Lemaitre Vascular cash flow, quarter by quarter

Latest: Q3 2026 · from the cash-flow statements filed with the SEC

Free cash flow$19.7M in Q3 2026 · $67.0M over twelve months

Operating cash flow$22.0M
Capital spending−$2.3M
Free cash flow+$19.7M
Cash / net income1.5×
Cash conversion cycle31 days

Analysis

In Q3 2026, Lemaitre Vascular generated $22.0M of operating cash flow and spent $2.3M on capital projects, leaving free cash flow of $19.7M. That is $6.8M less than in Q3 2025 ($26.5M).

Over the twelve months to Sep 30, 2026, operating cash flow was $76.2M; the largest uses were other investing ($46.0M), dividends ($21.7M), capital spending ($9.2M); besides operations, cash came from shares issued ($6.6M); the cash balance rose by $2.0M.

Operating cash flow was $22.0M against net income of $15.0M — 1.5× profit, cash ran ahead of reported earnings. The largest differences: payables +$5.8M, depreciation & amortization +$2.9M, prepaid and other assets −$2.9M.

Its cash conversion cycle was 31 days (receivables 48 + inventory 0 − payables 18).

Free cash flow

Lemaitre Vascular: free cash flow by quarterLemaitre Vascular: free cash flow by quarter$13.1MQ4 2024$7.7MQ1 2025$18.9MQ2 2025$26.5MQ3 2025$21.4MQ4 2025$12.3MQ1 2026$13.7MQ2 2026$19.7MQ3 2026
Operating cash flow less capital spending.
Lemaitre Vascular: operating cash flow against capital spendingLemaitre Vascular: operating cash flow against capital spendingOperating cash flowCapital spending$15.2M$2.0MQ4 2024$9.0M$1.4MQ1 2025$20.3M$1.3MQ2 2025$28.8M$2.3MQ3 2025$23.2M$1.8MQ4 2025$15.1M$2.8MQ1 2026$16.0M$2.3MQ2 2026$22.0M$2.3MQ3 2026
Latest (Q3 2026): Operating cash flow $22.0M, Capital spending $2.3M.

Capital allocation, year by year

Lemaitre Vascular: where the cash came from (up) and went (down), by fiscal yearLemaitre Vascular: where the cash came from (up) and went (down), by fiscal yearOperating cash flowNet borrowingShares issuedCapital spendingAcquisitionsBuybacksDividendsFY2021: Operating cash flow $35.1MFY2021: Shares issued $67.7MFY2021: Capital spending −$4.9MFY2021: Buybacks −$802KFY2021: Dividends −$9.3M$103MFY2021FY2022: Operating cash flow $25.4MFY2022: Shares issued $7.0MFY2022: Capital spending −$3.2MFY2022: Buybacks −$642KFY2022: Dividends −$11.0M$32.3MFY2022FY2023: Operating cash flow $36.8MFY2023: Shares issued $12.3MFY2023: Capital spending −$7.3MFY2023: Acquisitions −$899KFY2023: Buybacks −$853KFY2023: Dividends −$12.4M$49.1MFY2023FY2024: Operating cash flow $44.1MFY2024: Net borrowing $169MFY2024: Shares issued $12.9MFY2024: Capital spending −$7.0MFY2024: Buybacks −$1.7MFY2024: Dividends −$14.4M$226MFY2024FY2025: Operating cash flow $81.3MFY2025: Shares issued $6.8MFY2025: Capital spending −$6.8MFY2025: Acquisitions −$1.9MFY2025: Buybacks −$1.8MFY2025: Dividends −$18.1M$88.1MFY2025
Over these 5 years operating cash flow totalled $223M; the largest uses were dividends ($65.3M) and capital spending ($29.1M). Cash-flow statements as filed.

Cash runway and the debt wall

Cash & investments$390M
Debtnone
Net cash$390M

Lemaitre Vascular funds itself: free cash flow was $67.0M over the last twelve months, with $390M of cash and investments and no debt on the balance sheet.

Where the cash came from and went

Lemaitre Vascular: sources (+) and uses (−) of cash, Q3 2026Lemaitre Vascular: sources (+) and uses (−) of cash, Q3 2026Operating cash flow$22.0MOther investing−$13.8MDividends−$5.7MCapital spending−$2.3MCash drawn (+) / kept (−)−$868KShares issued$745KExchange rates$60KAcquisitions−$36K
Lemaitre Vascular: sources (+) and uses (−) of cash, TTM to Q3 2026Lemaitre Vascular: sources (+) and uses (−) of cash, TTM to Q3 2026Operating cash flow$76.2MOther investing−$46.0MDividends−$21.7MCapital spending−$9.2MShares issued$6.6MCash drawn (+) / kept (−)−$2.0MAcquisitions−$2.0MBuybacks−$1.7MExchange rates−$142KOther financing−$95K

From profit to cash

Lemaitre Vascular: net income to operating cash flow, Q3 2026Lemaitre Vascular: net income to operating cash flow, Q3 2026Net income$15.0MDepreciation & amortization$2.9MStock-based pay$2.0MReceivables−$470KPayables$5.8MPrepaid and other assets−$2.9MOperating cash flow$22.0M
Non-cash charges are added back; money tied up in receivables or inventory is subtracted.
QuarterReceivable daysInventory daysPayable daysCash conversion cycle
Q3 202648—1831
Q2 202646—1729
Q1 202647—1928
Q4 202547—1829
Q3 202552—2626
Q2 202551—1734
Q1 202549—1039
Q4 202451—942

Every quarter

QuarterOperating cash flowCapital spendingAcquisitionsBuybacksDividendsShares issuedCash drawn (+) / kept (−)Free cash flow
Q3 2026$22.0M−$2.3M−$36K—−$5.7M$745K−$868K$19.7M
Q2 2026$16.0M−$2.3M−$113K−$17K−$5.7M$776K$226K$13.7M
Q1 2026$15.1M−$2.8M−$45K−$460K−$5.7M$3.0M$1.4M$12.3M
Q4 2025$23.2M−$1.8M−$1.8M−$1.2M−$4.5M$2.2M−$2.8M$21.4M
Q3 2025$28.8M−$2.3M——−$4.5M$1.6M$1.7M$26.5M
Q2 2025$20.3M−$1.3M−$51K−$4K−$4.5M$1.8M−$1.8M$18.9M
Q1 2025$9.0M−$1.4M−$44K−$601K−$4.5M$1.3M$270K$7.7M
Q4 2024$15.2M−$2.0M—−$1.4M−$3.6M$1.3M−$4.6M$13.1M

Lemaitre Vascular: income statement and cash flow

Lemaitre Vascular, Q3 2026: revenue $68.0M (+11% year over year), operating margin 26.0%. The chart follows the revenue to costs, profit and cash.

Lemaitre Vascular: every quarter, Q/Q and Y/Y → Open in the app

Read automatically from the company’s XBRL cash-flow statements; quarterly figures for the fourth quarter are the year less the first three. Errors are possible. Not investment advice.